var data={"title":"Technetium Tc-99m oxidronate: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Technetium Tc-99m oxidronate: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/482850?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=technetium-tc-99m-oxidronate-patient-drug-information\" class=\"drug drug_patient\">see &quot;Technetium Tc-99m oxidronate: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13210110\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>TechneScan HDP</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13210112\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Radiopharmaceutical</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13210119\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Skeletal imaging: </b>IV: 15 mCi (555 MBq); range: 10 to 20 mCi (370 to 740 MBq); maximum dose: 20 mCi (740 MBq)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13210118\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Skeletal imaging: </b>IV: 0.2 mCi/kg (7.4 MBq/kg); range: 0.2 to 0.35 mCi/kg (7.4 to 13 MBq/kg); recommended total minimum dose: 1 mCi (37 MBq); maximum dose: 20 mCi (740 MBq)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22801902\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22801903\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46170896\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Kit, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">TechneScan HDP: Contents to be combined with sodium pertechnetate Tc99m injection solution (not included)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20223262\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">IV: For IV administration (slow IV injection). Imaging is optimal 1 to 4 hours after injection. Patients should be adequately hydrated before and after dosing; instruct patients to void immediately before imaging and frequently for 4 to 6 hours following administration to decrease radiation exposure to the bladder.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Radiopharmaceutical; use appropriate precautions for handling and disposal.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13210116\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Skeletal imaging:</b> Skeletal imaging agent to detect areas of altered osteogenesis in adult and pediatric patients.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13255277\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Other safety concerns:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Radiopharmaceutical: Use appropriate precaution for handling, disposal, and minimizing exposure to patients and healthcare personnel. Use under supervision of experienced personnel. Should be stored in original lead container or adequate radiation shield.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13210121\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">&lt;1%, postmarketing, and/or case reports: Hypersensitivity reaction (including severe hypersensitivity reactions), injection site reaction, nausea, vomiting</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49629745\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">There are no contraindications listed in the manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13210131\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypocalcemia: May form complexes with cations (eg, calcium); use with caution in hypocalcemic patients or in patients at risk to develop hypocalcemia.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>\n        <b>Concerns related to adverse effects:</b></i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity reactions: Hypersensitivity reactions, including life-threatening reactions, as well as nausea, vomiting and injection site reactions, have been reported.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special handling:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Radiopharmaceutical: Use appropriate precautions for handling, disposal, and minimizing exposure to patients and health care personnel. Use only under supervision of individuals with experience/training in the handling of radioactive materials approved by the applicable regulatory authority. <b>Note:</b> Contents of kit are not radioactive; however, adequate shielding is required after addition of radioactive material.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Patients should be adequately hydrated prior to and after dosing; instruct patients to void frequently for 4 to 6 hours following administration to decrease radiation exposure to the bladder.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13210136\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13210137\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Animal reproduction studies have not been conducted. Technetium Tc 99m can be detected in fetal tissue; the amount depends upon the specific formulation, route of administration, and stage of pregnancy (Adelstein, 1999).  </p>\n    <p style=\"text-indent:0em;margin-top:2em;\">In general, the potential for a radiopharmaceutical to cause fetal harm depends on the dose absorbed by the fetus and the stage of pregnancy. High doses of radiopharmaceuticals used for therapeutic procedures are more likely to result in fetal harm. A medically required diagnostic procedure can usually be modified to decrease fetal risk. Elective diagnostic procedures should be delayed until after delivery (Adelstein, 1999; ICRP, 2000; Parker, 2004). Pregnancy status should be determined in women of childbearing potential (Parker, 2004). The manufacturer recommends that elective procedures done in women of reproductive potential be conducted within the first few (~10) days following onset of menses.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13210139\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Technetium Tc 99m is present in breast milk. The manufacturer recommends substituting formula for breastfeeding. Due to low concentrations of technetium Tc 99m oxidronate found in breast milk, some sources note that interruption of breastfeeding is not essential depending on the dose, but recommend stopping for 4 hours (Harding 1995; Mountford 1988) while other sources recommended stopping breastfeeding for 12 hours (ICRP 2000).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">Following the administration of a radiopharmaceutical, women with a well-established milk supply should pump at normal feeding times and discard the milk until breastfeeding may be resumed (Harding 1995; Mountford 1989). Excretion of technetium Tc 99m into colostrum is widely variable and information is limited; therefore, recommendations related to early breastfeeding cannot be made (Mountford 1989; Rubow 1994). Elective diagnostic procedures should be delayed until breastfeeding has stopped (Parker 2004). Depending on the dose, compliance with regulatory requirements for instructions to the patient and recordkeeping may also be applicable (USNRC 1997).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50215715\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity reactions.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49629878\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Radioactive diagnostic agent which decays by isomeric transition to emit a photon that can be detected by imaging</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49629879\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:0em;margin-left:0em;display:inline\">Half-life elimination: Physical: ~6 hours</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F23777210\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Osteocis (ES, FI, FR, GB, IE, NL, PT);</li>\n      <li>Radpharm HDP (AU);</li>\n      <li>Technescan HDP (AU, BE, CH, CZ, DK, ES, FR, HU, IE, NL, NO, PT, SE)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Adelstein SJ, &quot;Administered Radionuclides in Pregnancy,&quot; <i>Teratology</i>, 1999, 59(4):236-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/technetium-tc-99m-oxidronate-drug-information/abstract-text/10331526/pubmed\" target=\"_blank\" id=\"10331526\">10331526</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ahlgren L, Ivarsson S, Johansson L, et al, &quot;Excretion of Radionuclides in Human Breast Milk After the Administration of Radiopharmaceuticals,&quot; <i>J Nucl Med</i>, 1985, 26(9):1085-90.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/technetium-tc-99m-oxidronate-drug-information/abstract-text/4032049/pubmed\" target=\"_blank\" id=\"4032049\">4032049</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Donohoe KJ, Brown ML, Collier BD, et al, &quot;Society of Nuclear Medicine Procedure Guideline for Bone Scintigraphy,&quot; 2003. Available at http://interactive.snm.org/docs/pg_ch34_0403.pdf. Last accessed August 31, 2011.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Harding LK, Bossuyt S, Pellet C, et al, &quot;Recommendations for Nuclear Medicine Physicians Regarding Breastfeeding Mothers,&quot; <i>Eur J Nucl Med</i>, 1995, 22(5)BP17.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    International Commission on Radiological Protection (ICRP), &quot;Pregnancy and Medical Radiation,&quot; <i>Ann ICRP</i>, 2000, 30(1):iii-viii, 1-43.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/technetium-tc-99m-oxidronate-drug-information/abstract-text/11108925/pubmed\" target=\"_blank\" id=\"11108925\">11108925</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mountford PJ and Coakley AJ, &quot;A Review of the Secretion of Radioactivity in Human Breast Milk: Data, Quantitative Analysis and Recommendations,&quot; <i>Nucl Med Commun</i>, 1989, 10(1):15-27.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/technetium-tc-99m-oxidronate-drug-information/abstract-text/2645546/pubmed\" target=\"_blank\" id=\"2645546\">2645546</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Parker JA, Daube-Witherspoon ME, Graham LS, et al, &quot;Procedure Guideline For General Imaging: 3.0,&quot; Society of Nuclear Medicine, 2004. Available at http://interactive.snm.org/docs/General_Imaging_v3.0.pdf</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rubow S, Klopper J, Wasserman H, et al, &quot;The Excretion of Radiopharmaceuticals in Human Breast Milk: Additional Data and Dosimetry,&quot; <i>Eur J Nucl Med</i>, 1994, 21(2):144-53.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/technetium-tc-99m-oxidronate-drug-information/abstract-text/8162938/pubmed\" target=\"_blank\" id=\"8162938\">8162938</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    TechneScan HDP (technetium Tc 99m oxidronate) [prescribing information]. Maryland Heights, MO: Mallinckrodt Nuclear Medicine LLC; March 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    U.S. Nuclear Regulatory Commission (USNRC), &quot;Regulatory Guide 8.39. Release of Patients Administered Radioactive Materials,&quot; 1997.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 16815 Version 47.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F13210110\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F13210112\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F13210119\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F13210118\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F22801902\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F22801903\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F46170896\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F20223262\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F13210116\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F13255277\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F13210121\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F49629745\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F13210131\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F13210136\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F13210137\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F13210139\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F50215715\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F49629878\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F49629879\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F23777210\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/16815|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=technetium-tc-99m-oxidronate-patient-drug-information\" class=\"drug drug_patient\">Technetium Tc-99m oxidronate: Patient drug information</a></li></ul></div></div>","javascript":null}